Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 4, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

A new look at node-negative breast cancer.

Nadia Harbeck1, Christoph Thomssen

  • 1Breast Center, University of Cologne, Cologne, Germany. nadia.harbeck@uk-koeln.de

The Oncologist
|February 1, 2011
PubMed
Summary

Identifying the right patients for chemotherapy in node-negative breast cancer is crucial. New biomarkers are needed to accurately predict which patients will benefit from adjuvant chemotherapy, improving treatment selection.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prospective validation of the prognostic and predictive impact of uPA/PAI-1 in early breast cancer.

Breast cancer research and treatment·2025
Same author

AGO Breast Commission recommendations for the surgical therapy of breast cancer: Working Group on Gynecologic Cancers (AGO) update 2025.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2025
Same author

Invasive disease-free and overall survival after (neo)adjuvant chemotherapy in postmenopausal patients with hormone receptor-positive, HER2-negative early breast cancer treated with upfront letrozole: Experiences from the phase IV PreFace trial.

International journal of cancer·2025
Same author

St. Gallen/Vienna 2025 Summary of Key Messages on Therapy in Early Breast Cancer from the 2025 St. Gallen International Breast Cancer Conference.

Breast care (Basel, Switzerland)·2025
Same author

AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2025.

Breast care (Basel, Switzerland)·2025
Same author

Association of statin use on survival outcomes of patients with early-stage HER2-positive breast cancer in the APHINITY trial.

Breast cancer research and treatment·2025

Area of Science:

  • Oncology
  • Biomarker Research
  • Breast Cancer Treatment

Background:

  • Node-negative breast cancer is common globally, necessitating specific risk assessment.
  • Current prognostic factors for node-negative breast cancer are insufficient for guiding chemotherapy decisions.
  • Chemotherapy is often broadly administered due to a lack of precise predictive markers.

Purpose of the Study:

  • To highlight the challenges in risk stratification for node-negative breast cancer.
  • To discuss existing and emerging biomarkers for predicting chemotherapy benefit.
  • To emphasize the need for improved patient selection in adjuvant chemotherapy.

Main Methods:

  • Review of current clinical practices and prognostic factors for node-negative breast cancer.
  • Evaluation of established tools like tumor grade and Adjuvant! Online.
  • Discussion of novel biomarker assays such as urokinase-type plasminogen activator (uPA)/plasminogen activator inhibitor type 1 (PAI-1) and Oncotype DX®.

Main Results:

  • No single prognostic factor reliably guides chemotherapy decisions in node-negative breast cancer.
  • uPA/PAI-1 assays require fresh-frozen tissue, limiting applicability.
  • Oncotype DX® is under evaluation, showing promise for prognosis estimation.

Conclusions:

  • Proper patient selection for adjuvant chemotherapy remains a significant challenge in node-negative breast cancer.
  • Existing biomarkers have limitations in accuracy and feasibility.
  • Further research into novel biomarkers is essential to optimize treatment for these patients.

More Related Videos

Single-port Non-liposuction Endoscopic Axillary Lymph Node Dissection in Breast Cancer Surgery
11:49

Single-port Non-liposuction Endoscopic Axillary Lymph Node Dissection in Breast Cancer Surgery

Published on: April 3, 2026

Related Experiment Videos

Last Updated: Jun 4, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

Single-port Non-liposuction Endoscopic Axillary Lymph Node Dissection in Breast Cancer Surgery
11:49

Single-port Non-liposuction Endoscopic Axillary Lymph Node Dissection in Breast Cancer Surgery

Published on: April 3, 2026